Skip to main content
Article thumbnail
Location of Repository

Atorvastatin Reduces Plasma Levels of Chemokine (CXCL10) in Patients with Crohn's Disease

By Olof Grip and Sabina Janciauskiene
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2005). Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.
    2. (2005). Anti-interferoninducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice.
    3. (2002). Atorvastatin inhibition of cytokineinducible nitric oxide synthase expression in native endothelial cells in situ.
    4. (1999). Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
    5. (1987). Biochemical characterization of a gamma interferon-inducible cytokine (IP-10).
    6. (2008). Bredberg A
    7. (2007). Carding SR
    8. (2003). Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn’s disease.
    9. (1996). Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes.
    10. (2007). Chemokine: receptor structure, interactions, and antagonism.
    11. (1998). Chemokines and leukocyte traffic.
    12. (2008). Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease.
    13. (2004). Chemokines: role in inflammation and immune surveillance.
    14. (2004). Circulating monocytes and plasma inflammatory biomarkers in active Crohn’s disease: elevated oxidized lowdensity lipoprotein and the anti-inflammatory effect of atorvastatin.
    15. (2005). Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
    16. (2007). Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease.
    17. (2007). CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets
    18. (2001). CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells.
    19. (2001). Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways.
    20. (2005). Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes.
    21. (2001). Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
    22. (2005). Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease.
    23. (2007). Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    24. (1997). Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease.
    25. (2005). Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis.
    26. (1999). Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils.
    27. (2003). Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
    28. (1999). Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis.
    29. (2001). Increased serum levels of eotaxin in patients with inflammatory bowel disease.
    30. (2003). Inhibition of IFN-gammainducible protein-10 abrogates colitis in IL-102/2 mice.
    31. (1999). Inhibition of proinflammatory cytokine production by pravastatin.
    32. (2007). Intracellular JNK, p38 MAPK and NFkappaB regulate IL-25 induced release of cytokines and chemokines from costimulated T helper lymphocytes.
    33. (2002). Isoprenoids as mediators of the biological effects of statins.
    34. (1998). Lanzavecchia A
    35. (2005). Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn’s disease.
    36. (1997). Nuclear factor-kappa B.
    37. (2003). Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity.
    38. (1996). Protein prenylation: molecular mechanisms and functional consequences.
    39. (2001). Quantitation of chemokines (MDC, TARC) expression in mucosa from Crohn’s disease and ulcerative colitis.
    40. (2001). Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells.
    41. (2001). Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 gamma) MAP kinase pathway.
    42. (1998). Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells.
    43. (2000). Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins.
    44. (2002). T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis.
    45. (1998). The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.
    46. (1999). The chemokine system: redundancy for robust outputs.
    47. (2008). The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
    48. (2002). The role of chemokines in linking innate and adaptive immunity.
    49. (2004). The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.